Replimune REPL
NASDAQ REPL
$11.99 +0.27 (+2.30%)
At close: Oct 22, 2026 · 4:00 PM EDT

Replimune (REPL) Amortization of Deferred Charges (2024 - 2026)

Updated

Analysis

Replimune (REPL) Amortization of Deferred Charges (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Replimune 1.15 Bn 89.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 607,000.00
Mar 31, 2026 607,000.00
Dec 31, 2025 607,000.00
Sep 30, 2025 607,000.00
Jun 30, 2025 607,000.00
Mar 31, 2025 607,000.00
Dec 31, 2024 607,000.00
Sep 30, 2024 607,000.00
Jun 30, 2024 607,000.00
API Access

Replimune Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=REPL&period=max&api_key=YOUR_API_KEY